R26-rtTA/TIGRE-pTRE-hDMPK(exon 11-15)

Nomenclature

C57BL/6JSmo-Gt(ROSA)26Sorem1(CAG-M2rtTA-WPRE-pA)Igs7tm1(2xIns-DMPK 5‘region-pTRE-hDMPK(exon 11-15)-3'UTR(CTG)200-DMPK 1st intron-pA-2xIns)Smoc

Cat. NO.

NM-XA-252292

Strain State

Repository Live

Export PDF

Model Description

The R26-rtTA (NM-KI-232260) was crossed with TIGRE-pTRE-hDMPK(exon 11-15)(NM-KI-232261) to generate R26-rtTA/TIGRE-pTRE-hDMPK(exon 11-15) mice.

Validation Data

image.png

Fig.1 Detection of hDMPK(exon 11-15)-3'UTR(CTG)200-DMPK  expression in muscle and heart by qPCR. 

Each value in G1 and G2 represents the mRNA level relative to the value in G3(n=3).

Abbr. WT, wild type. Doxy, Doxycycline.

image.png

Fig.2 Body weight growth curve of R26-rtTA-TIGRE-DM200 (Doxy) mice. Doxy administration start from 6-8 weeks old.

Abbr. WT, Wild type; Doxy, Doxycycline.

image.png

Fig.3 8 weeks post doxy induction, (A-C) significant skeletal muscle wasting is observed in gastrocnemius and tibialis anterior (TA) muscles from R26-rtTA-TIGRE-DM200 (Doxy) mice. (D) Tibia length is unaffected in R26-rtTA-TIGRE-DM200 (Doxy) mice compared with C57BL/6. (E) Representative image of detection of muscle loss(arrows). (n=3). *P<0.05, **P<0.01, ***P<0.001

Abbr. WT, Wild type; Doxy, Doxycycline.

image.png

Fig.4 Histopathology of C57BL6 and R26-rtTA-TIGRE-DM200 (Doxy) mice at 8 weeks post doxy induction. (A) H&E staining images of Gastrocnemius. (B) Fiber CSA (143 fibers per sample). Quantified in (C). (n=3). 

Abbr. WT, Wild type; Doxy, Doxycycline; CSA, Cross Sectional Area.


You may also like

Workshop:Progress and Advances in Preclinical immuno-Oncology Research

SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.

Learn more

Shanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute

On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.

Learn more

Customizing Mouse Models: Delivering in 100 Days to Speed Up Your Research!

At GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.

Learn more